Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. develops live biotherapeutic products and microbiome-based therapies for inflammatory, immune, infectious and gastrointestinal diseases. Company updates commonly address pipeline programs such as SER-155 for immune checkpoint inhibitor-related enterocolitis and prevention of bloodstream infections in allogeneic hematopoietic stem cell transplant patients, SER-603 for inflammatory bowel disease, and SER-428 for antimicrobial resistance and serious infections.
Recurring announcements include financial results, operational updates, research publications, scientific conference presentations, biomarker and microbiome-mechanism data, collaborations, financing and partnership activity, cost-control measures, and governance changes.
Seres Therapeutics (MCRB) reported significant progress in its microbiome therapeutic SER-109, with confirmatory Phase 3 study results showing a sustained clinical response in 91.3% of recurrent C. difficile infection patients. The company initiated a rolling Biologics License Application (BLA) submission, expected to be completed soon. Financially, Seres strengthened its position with a $100 million equity offering, bringing its pro-forma cash balance to approximately $291.4 million. Despite a net loss of $64.7 million for Q2 2022, the company remains optimistic about SER-109's commercial potential.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on August 3, 2022 at 8:30 a.m. ET to discuss its second quarter results and provide a business update.
Seres is noted for its SER-109 program, which has achieved significant clinical results in targeting C. difficile infections, receiving both Breakthrough Therapy and Orphan Drug designations from the FDA. The company is also advancing its SER-155 program to reduce infections in patients undergoing stem cell transplants.
Seres Therapeutics (MCRB) announced a registered direct offering of 31,746,030 shares at $3.15 per share, generating approximately $100 million in gross proceeds. The offering, which includes participation from notable investors like Federated Hermes and Nestlé Health Science, is expected to close on July 5, 2022. Proceeds will be used for the commercial readiness and manufacturing of SER-109 for the U.S. market and advancing its clinical development in the EU. The offering is conducted under a shelf registration statement filed with the SEC.
Seres Therapeutics (NASDAQ: MCRB) announced favorable results from the ECOSPOR IV study for SER-109, an oral microbiome therapy for recurrent C. difficile infection. The study showed a 91.3% sustained clinical response at eight weeks and confirmed a favorable safety profile, consistent with the previous ECOSPOR III study. A rolling Biologics License Application (BLA) submission has been initiated, with completion anticipated by mid-2022. The company aims for a potential launch in the first half of 2023, supported by FDA Breakthrough Therapy designation.
Seres Therapeutics, Inc. (MCRB) presented preclinical data highlighting the efficacy of the investigational microbial consortium DE486 in reducing chemotherapy-induced mucositis. The findings will be discussed at the 2022 ASCO Annual Meeting. Additionally, a Phase 1b trial of SER-155 is being conducted to assess its safety and efficacy in preventing complications during stem cell transplants. The company also plans to present Phase III results of SER-109 for recurrent C. difficile infection, which showed a lower recurrence rate than placebo. SER-109 is expected to submit a BLA to the FDA in mid-2022.
Seres Therapeutics, Inc. (Nasdaq: MCRB) presented promising data from its Phase 3 ECOSPOR III study, demonstrating that SER-109 effectively prevents recurrent C. difficile infections by establishing beneficial gut microbes. After one week of treatment, SER-109 increased microbiome diversity, producing fatty acids that inhibit C. difficile growth. The therapy showed an 88% success rate in preventing infection recurrence at eight weeks. Seres aims to submit a Biologics License Application by mid-2022, potentially leading to the first FDA-approved microbiome therapeutic by early 2023.
Seres Therapeutics (Nasdaq: MCRB) announced the presentation of its ECOSPOR III trial data for SER-109 at the Digestive Disease Week (DDW) Annual Meeting, scheduled for May 21-24, 2022. SER-109 is an investigational oral microbiome therapy aimed at preventing recurrent C. difficile infections. The company plans to submit a Biologics License Application (BLA) to the FDA in mid-2022. Presentations include an oral session on SER-109's impact on stool fatty acid metabolites and a poster on its durable engraftment. SER-109 has FDA Breakthrough and Orphan Drug designations.
Seres Therapeutics reported Q1 2022 results, highlighting significant progress with SER-109 for recurrent C. difficile infection (rCDI). The FDA approved a rolling submission for the Biologics License Application (BLA), targeting completion by mid-2022. SER-109 demonstrated superior efficacy with 88% of patients achieving sustained responses. The company faced a net loss of $56.6 million, an increase from $35.5 million the previous year, primarily driven by rising R&D costs. Seres ended the quarter with $248 million in cash, down from $291 million at the end of 2021, indicating potential cash burn risks.
Seres Therapeutics, Inc. (NASDAQ: MCRB) announced a conference call on May 4, 2022, at 8:30 a.m. ET to discuss its first quarter results and provide a business update. The call can be accessed by dialing 877-270-2148 (domestic) or 412-902-6510 (international). The company is known for its innovative microbiome therapeutics, particularly the SER-109 program, which has received Breakthrough Therapy and Orphan Drug designations from the FDA. SER-109 aims to reduce C. difficile infection recurrence, marking a significant milestone in microbiome-based treatments.
Seres Therapeutics (Nasdaq: MCRB) presents promising preclinical data on SER-155 at the European Bone Marrow Transplantation Annual Meeting. The findings indicate that SER-155 can potentially reduce infections and Graft-versus-Host Disease (GvHD) in patients undergoing hematopoietic stem cell transplantation. The ongoing Phase 1b clinical trial aims to evaluate SER-155's safety and efficacy after vancomycin treatment. Preliminary results show SER-155 enhances gut immunity and may restore a healthy microbiome, addressing a critical need in transplant recovery.